Correlation Between Veracyte and Aileron Therapeutics

Can any of the company-specific risk be diversified away by investing in both Veracyte and Aileron Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Veracyte and Aileron Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Veracyte and Aileron Therapeutics, you can compare the effects of market volatilities on Veracyte and Aileron Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Veracyte with a short position of Aileron Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Veracyte and Aileron Therapeutics.

Diversification Opportunities for Veracyte and Aileron Therapeutics

-0.8

Correlation Coefficient

Veracyte  Aileron Therapeutics

Pay attention - limited upside

The 3 months correlation between Veracyte and Aileron is -0.8. Overlapping area represents the amount of risk that can be diversified away by holding Veracyte and Aileron Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Aileron Therapeutics and Veracyte is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Veracyte are associated (or correlated) with Aileron Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Aileron Therapeutics has no effect on the direction of Veracyte i.e., Veracyte and Aileron Therapeutics go up and down completely randomly.

Pair Corralation between Veracyte and Aileron Therapeutics

Given the investment horizon of 90 days Veracyte is expected to generate 0.41 times more return on investment than Aileron Therapeutics. However, Veracyte is 2.43 times less risky than Aileron Therapeutics. It trades about 0.05 of its potential returns per unit of risk. Aileron Therapeutics is currently generating about 0.02 per unit of risk. If you would invest  2,265  in Veracyte on September 23, 2024 and sell it today you would earn a total of  1,824  from holding Veracyte or generate 80.53% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Significant
Accuracy	100.0%
Values	Daily Returns

Veracyte  vs.  Aileron Therapeutics

Veracyte

Risk-Adjusted Performance

8 of 100

OK

Compared to the overall equity markets, risk-adjusted returns on investments in Veracyte are ranked lower than 8 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively unsteady basic indicators, Veracyte unveiled solid returns over the last few months and may actually be approaching a breakup point.

Aileron Therapeutics

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Aileron Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unsteady performance in the last few months, the Stock's basic indicators remain very healthy which may send shares a bit higher in January 2025. The recent disarray may also be a sign of long period up-swing for the firm investors.

Pair Trading with Veracyte and Aileron Therapeutics

The main advantage of trading using opposite Veracyte and Aileron Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Veracyte position performs unexpectedly, Aileron Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Aileron Therapeutics will offset losses from the drop in Aileron Therapeutics' long position.

The idea behind Veracyte and Aileron Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.